Skip to content

Madrigal Pharmaceuticals

US · MDGL #1355 by market cap Listed 2016
379.10 -17.64 -4.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 396.14 -0.15%
After-hours 379.10 0.00%
565.40379.10379.102026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MDGL?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -28.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 9.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D-

The radar needs all six factors. Available grades are shown below.

Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 49.4x Better than 7%
Price / Sales 7.0x Better than 15%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 94.1% Better than 98%
Operating margin -31.3% Better than 10%
Net margin -30.1% Better than 11%
Return on equity -42.5% Better than 10%
Return on invested capital -33.3% Better than 9%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -26.6% Better than 21%
6-month return -26.7% Better than 21%
12-month return (ex latest month) -20.8% Better than 15%
Distance below 52-week high 38.4% Better than 30%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.0x Better than 81%
Debt to assets 27.6% Better than 45%
Interest coverage -11.9x Better than 12%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 88.9% Better than 72%
Upside to average target 85.3% Better than 80%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.30%
1M -18.92%
3M -26.97%
6M -26.17%
YTD -34.90%
1Y -30.07%
3Y +99.47%
5Y +360.07%

Key statistics

Price & volume

Prev close
396.74
Open
396.74
Day range
377.90 - 399.43
Avg price
385.44
Volume
327.84K
Turnover
126.36M
Amplitude
5.43%
52-week range
353.54 - 615.00

Valuation

P/E
-29.50
P/E (TTM)
-47.09
P/B
14.05
EPS
-12.85
Net profit
-298.50M
Net assets
626.94M

Share structure

Market cap
8.81B
Float cap
5.99B
Shares out
23.23M
Float shares
15.80M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-07-25
52-week range 10% of range
353.54 615.00

38.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-20.37M net over the window

Short interest

Shares short
2.14M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals last traded at 379.10. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Madrigal Pharmaceuticals's market cap?

About 8.81B.

What is the P/E ratio of Madrigal Pharmaceuticals?

The trailing twelve-month P/E is -47.09. The Valuation tab shows it against the stock's own five-year range.

Does Madrigal Pharmaceuticals pay a dividend?

Madrigal Pharmaceuticals does not currently pay a regular dividend.

Is Madrigal Pharmaceuticals a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 702.33, which implies 85.3% upside from the current price. This is not investment advice.

What is Madrigal Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Madrigal Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Madrigal Pharmaceuticals discussion 0 comments

Add a comment